Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): Study protocol for a randomized controlled trial

Dong Ju Choi, Chan Soon Park, Jin Joo Park, Hae Young Lee, Seok Min Kang, Byung Su Yoo, Eun Seok Jeon, Seok Keun Hong, Joon Han Shin, Myung A. Kim, Dae Gyun Park, Eung Ju Kim, Soon Jun Hong, Seok Yeon Kim, Jae Joong Kim

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)

    Abstract

    Background: Carvedilol is a non-selective, third-generation beta-blocker and is one of the cornerstones for treatment for patients with heart failure and reduced ejection fraction (HFrEF). However, due to its short half-life, immediate-release carvedilol (IR) needs to be prescribed twice a day. Recently, slow-release carvedilol (SR) has been developed. The aim of this study is to evaluate whether carvedilol-SR is non-inferior to standard carvedilol-IR in terms of its clinical efficacy in patients with HFrEF. Methods/design: Patients with stable HFrEF will be randomly assigned in a 1:1 ratio to the carvedilol-SR group (160 patients) and the carvedilol-IR group (160 patients). Patients aged ≥ 20 years, with a left ventricular ejection fraction ≤ 40%, N-terminal pro B-natriuretic peptide (NT-proBNP) ≥ 125 pg/ml or BNP ≥ 35 pg/ml, who are clinically stable and have no evidence of congestion or volume retention, will be eligible. After randomization, patients will be followed up for 6 months. The primary endpoint is the change in NT-proBNP level from baseline to the study end. The secondary endpoints include the proportion of patients with NT-proBNP increment > 10% from baseline, composite of all-cause mortality and readmission, mortality rate, readmission rate, changes in blood pressure, quality of life, and drug compliance. Discussions: The SLOW-HF trial is a prospective, randomized, open-label, phase-IV, multicenter study to evaluate the therapeutic efficacy of carvedilol-SR compared to carvedilol-IR in HFrEF patients. If carvedilol-SR proves to be non-inferior to carvedilol-IR, a once-daily prescription of carvedilol may be recommended for patients with HFrEF.

    Original languageEnglish
    Article number103
    JournalTrials
    Volume19
    Issue number1
    DOIs
    Publication statusPublished - 2018 Feb 13

    Keywords

    • Carvedilol
    • Clinical efficacy
    • Heart failure with reduced ejection fraction
    • Immediate release
    • NT-proBNP
    • Slow release

    ASJC Scopus subject areas

    • Medicine (miscellaneous)
    • Pharmacology (medical)

    Fingerprint

    Dive into the research topics of 'Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): Study protocol for a randomized controlled trial'. Together they form a unique fingerprint.

    Cite this